MiMedx Group (MDXG) Competitors $6.66 -0.12 (-1.77%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$6.66 0.00 (-0.08%) As of 07/11/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDXG vs. NVST, PRCT, LIVN, WRBY, NVCR, ENOV, LMAT, EYE, CNMD, and AORTShould you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Envista (NVST), PROCEPT BioRobotics (PRCT), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), Enovis (ENOV), LeMaitre Vascular (LMAT), National Vision (EYE), CONMED (CNMD), and Artivion (AORT). These companies are all part of the "medical equipment" industry. MiMedx Group vs. Its Competitors Envista PROCEPT BioRobotics LivaNova Warby Parker NovoCure Enovis LeMaitre Vascular National Vision CONMED Artivion MiMedx Group (NASDAQ:MDXG) and Envista (NYSE:NVST) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Which has better valuation & earnings, MDXG or NVST? MiMedx Group has higher earnings, but lower revenue than Envista. Envista is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiMedx Group$348.88M2.82$42.42M$0.2724.67Envista$2.51B1.36-$1.12B-$6.53-3.09 Which has more volatility and risk, MDXG or NVST? MiMedx Group has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, Envista has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500. Do analysts prefer MDXG or NVST? MiMedx Group presently has a consensus price target of $12.50, indicating a potential upside of 87.69%. Envista has a consensus price target of $20.23, indicating a potential upside of 0.20%. Given MiMedx Group's stronger consensus rating and higher possible upside, equities analysts clearly believe MiMedx Group is more favorable than Envista.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Envista 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.33 Do insiders and institutionals believe in MDXG or NVST? 79.2% of MiMedx Group shares are owned by institutional investors. 1.7% of MiMedx Group shares are owned by company insiders. Comparatively, 1.3% of Envista shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is MDXG or NVST more profitable? MiMedx Group has a net margin of 11.40% compared to Envista's net margin of -44.90%. MiMedx Group's return on equity of 22.70% beat Envista's return on equity.Company Net Margins Return on Equity Return on Assets MiMedx Group11.40% 22.70% 16.77% Envista -44.90%4.07%2.25% Does the media prefer MDXG or NVST? In the previous week, Envista had 4 more articles in the media than MiMedx Group. MarketBeat recorded 6 mentions for Envista and 2 mentions for MiMedx Group. MiMedx Group's average media sentiment score of 1.52 beat Envista's score of 0.98 indicating that MiMedx Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiMedx Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Envista 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMiMedx Group beats Envista on 13 of the 17 factors compared between the two stocks. Get MiMedx Group News Delivered to You Automatically Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDXG vs. The Competition Export to ExcelMetricMiMedx GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$983.70M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio24.6720.8528.2620.26Price / Sales2.82303.05437.10166.10Price / Cash20.1042.1137.1257.67Price / Book5.087.638.045.49Net Income$42.42M-$55.05M$3.19B$250.45M7 Day Performance5.97%8.43%3.62%4.79%1 Month Performance10.26%8.14%5.98%9.59%1 Year Performance-6.59%1.62%29.39%16.41% MiMedx Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDXGMiMedx Group3.7086 of 5 stars$6.66-1.8%$12.50+87.7%-6.6%$983.70M$348.88M24.67870News CoveragePositive NewsNVSTEnvista3.2771 of 5 stars$19.66-3.6%$20.23+2.9%+26.0%$3.46B$2.51B-3.0112,300Analyst ForecastPRCTPROCEPT BioRobotics2.2971 of 5 stars$56.97-1.6%$90.00+58.0%-18.3%$3.20B$249.12M-33.51430News CoverageAnalyst ForecastLIVNLivaNova3.1135 of 5 stars$45.58-1.2%$59.29+30.1%-13.8%$2.52B$1.25B-11.142,900News CoverageWRBYWarby Parker2.47 of 5 stars$21.40-3.8%$22.88+6.9%+37.2%$2.32B$771.32M-178.333,780News CoverageAnalyst DowngradeNVCRNovoCure3.6691 of 5 stars$16.89-4.6%$32.83+94.4%-2.1%$1.97B$605.22M-11.191,488Analyst ForecastENOVEnovis2.6083 of 5 stars$33.03-1.8%$58.00+75.6%-26.1%$1.92B$2.11B-2.377,367Analyst ForecastLMATLeMaitre Vascular2.2802 of 5 stars$82.98-1.7%$97.83+17.9%-2.8%$1.91B$219.86M41.91490News CoverageEYENational Vision2.554 of 5 stars$23.33-2.4%$18.67-20.0%+93.1%$1.89B$1.82B-70.6913,411News CoverageAnalyst ForecastCNMDCONMED4.4364 of 5 stars$51.86-4.5%$62.20+19.9%-25.1%$1.68B$1.31B13.653,900AORTArtivion2.6642 of 5 stars$30.22-1.6%$32.40+7.2%+15.3%$1.31B$388.54M-60.441,600 Related Companies and Tools Related Companies Envista Alternatives PROCEPT BioRobotics Alternatives LivaNova Alternatives Warby Parker Alternatives NovoCure Alternatives Enovis Alternatives LeMaitre Vascular Alternatives National Vision Alternatives CONMED Alternatives Artivion Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDXG) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDXG Stock Alerts